| Date | Title | Description |
| 06.03.2026 | Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’ | Shares of Danish drugmaker Zealand Pharma fell more than 35% after trial patients lost less weight than expected with its experimental medicine.
CEO Adam Steensberg told CNBC that, in the real world, Zealand’s drug offers massive potential ... |
| 20.02.2026 | Buy this best-in-class GLP-1 leader as competition heats up, says Barclays | - |
| 29.01.2026 | Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite | Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock.
As pharma companies face a “patent cliff” where existing drugs lose exclusivity, the companies talked up what they have in ... |
| 12.01.2026 | Zealand Pharma Enters Agreement With Dcai to Use Gefion AI Supercomputer to Accelerate Drug Discovery and Support Metabolic Frontier 2030 Strategy | Zealand Pharma A/S, a biotechnology company transforming the future of metabolic health, announces an agreement with DCAI, an AI infrastructure company which operates Gefion, Denmark’s supercomputer, to strengthen and accelerate drug discov... |
| 23.12.2025 | European markets close at fresh high in final full session before Christmas | LONDON — European markets closed higher on Tuesday, paring the previous session’s losses.
The pan-European Stoxx 600 closed up 0.3%, notching a new record closing high, lifted by surging shares of Copenhagen-listed Novo Nordisk.
That brings... |
| 11.12.2025 | OTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases | Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for mul... |
| 11.12.2025 | Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly | Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its “Metabolic Frontier 2030” strategy.
The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment... |
| 13.11.2025 | European markets lose earlier gains as U.S. shutdown ends | LONDON — European stocks ended lower on Thursday, paring earlier gains as the U.S. government shutdown came to an end.
The pan-European Stoxx 600 finished down 0.6% with most sectors and bourses in negative territory.
The U.K.’s FTSE 100 in... |
| 10.11.2025 | Europe markets close higher as hopes of an end to U.S. government shutdown spill over | LONDON — European stocks rallied on Monday as a deal on a funding package that could end the U.S. government shutdown appears to be getting closer.
The pan-European Stoxx 600 closed the session 1.4% higher, with major bourses and almost all... |
| 01.10.2025 | European pharma stocks close higher amid C-level shake-ups and listing chatter | European markets closed higher on Wednesday, as investors monitor the U.S. government shutdown.
The pan-European Stoxx 600 finished trading up 1.2%, with most sectors and major bourses in positive territory.
Stocks are picking up from a pos... |
| 18.09.2025 | European stocks end higher with monetary policy in focus; Zealand Pharma gains 8% | LONDON — European stocks moved higher on Thursday, as traders evaluated the latest monetary policy updates from the Bank of England and the Federal Reserve.
The pan-European Stoxx 600 provisionally closed 0.8% higher, with most sectors and ... |
| 16.09.2025 | Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster | Cagrilintide is a long-acting amylin analogue, a nascent form of weight loss treatment which differs existing GLP-1s.
Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection helped patients reduce their weight by 11.... |
| 26.08.2025 | A world on weight loss drugs: How GLP-1s are reshaping the economy | Obesity drugs, or GLP-1s, have had a transformative effect on Wall Street and waistlines over recent years.
As adoption grows and new applications for the drugs come to light, experts say that could have sweeping outcomes for both health an... |
| 10.06.2025 | Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care | PARIS, June 10, 2025 /PRNewswire/ -- As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, the ... |
| 28.05.2025 | The Trade Tug-of-War: Trump’s Tariff Tango with the EU | In the world of trade, every word can tip the scales. Recently, President Donald Trump reignited tensions with the European Union (EU) by threatening a staggering 50% tariff on EU goods. This announcement sent shockwaves through global mark... |
| 27.05.2025 | Cereno Scientific is nominated and shortlisted for ‘Company of the Year’ in the European Mediscience Awards 2025 | Cereno Scientific is nominated and shortlisted for ‘Company of the Year’ in the European Mediscience Awards 2025
Tue, May 27, 2025 08:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneerin... |
| 26.05.2025 | European stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10% | European shares were higher on Monday as investors reacted to U.S. President Donald Trump delaying the roll out of 50% tariffs on the European Union.
The pan-European Stoxx 600 provisionally ended up 1%, with all sectors in positive territo... |
| 22.04.2025 | Europe markets close higher; ECB’s Lagarde says euro zone disinflation ‘nearing completion’ | This was CNBC’s live blog covering European markets.
European markets climbed into the green on Tuesday, shaking off earlier losses as European Central Bank President Christine Lagarde told CNBC the disinflation process in the euro area was... |
| 25.03.2025 | The Weight of Expectations: A Look at the Obesity Drug Market's Rollercoaster Ride | The obesity drug market is a battleground, where hopes soar and plummet with each trial result. Recent developments from Novo Nordisk and Eli Lilly illustrate this volatile landscape. Both companies are vying for dominance in a sector proje... |
| 24.03.2025 | Novo Nordisk’s next-gen obesity drug CagriSema had investors excited. Now they’re not so sure | Novo Nordisk’s latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs.
CagriSema, which includes a nascent form of weight loss treatment known as an ... |
| 14.03.2025 | Tariff Tensions and Market Reactions: A Delicate Balance | In the world of finance, news travels fast. The markets are like a finely tuned orchestra, responding to the slightest change in the melody of economic indicators. Recently, the U.S. economy has been caught in a whirlwind of tariff threats ... |
| 13.03.2025 | CNBC Daily Open: A muted inflation report for February supported markets even as the trade war heats up | CNBC will be hosting “CONVERGE LIVE,” an inaugural thought leadership event on March 12-13, 2025, in Singapore, where global business leaders, entrepreneurs, investors and key decision-makers will discuss what it means to innovate and grow ... |
| 12.03.2025 | Europe markets close higher despite U.S.-EU tariff escalation as Ukraine peace hopes buoy sentiment | This was CNBC’s live blog covering European markets.
European markets saw broad gains on Wednesday, even after the European Union announced retaliatory tariffs on a swathe of U.S. imports and President Donald Trump suggested further counter... |
| 12.03.2025 | Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma | Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma’s obesity drug candidate.
Shares of Zealand Pharma jumped as much as 38%, while Roche added 4%.
Zeal... |
| 20.12.2024 | Novo Nordisk Faces a Storm: CagriSema Trial Results Sink Shares | In the high-stakes world of pharmaceuticals, expectations can soar as high as a kite. But when reality strikes, the fall can be swift and brutal. Novo Nordisk, a titan in the obesity drug market, recently faced such a reckoning. The company... |
| 20.12.2024 | Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints | Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
By Maggie Fick and Jacob Gronholt-PedersenDecember 20, 20245:52 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
SummaryC... |
| 11.11.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | Company announcement – No. 50 / 2024
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, November 11, 2024 – Zealand... |
| 30.08.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | Company announcement – No. 43 / 2024
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, August 30, 2024 – Zealand P... |
| 08.07.2024 | Danish pole position among best Nordic life science stocks in H1 | Danish pole position among best Nordic life science stocks in H1
Mon, Jul 08, 2024 07:45 CET Report this content
The first six months of 2024 have passed and it is time to swap the ergonomically designed office chair for a sunbed At BioStoc... |
| 25.06.2024 | Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion | Company announcement – No. 33 / 2024
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR IN... |
| 20.06.2024 | Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide | Company announcement – No. 32 / 2024
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Body weight reductions of up to a mean of 8.... |
| 29.05.2024 | Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 | Press release – No. 5 / 2024
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on... |
| 04.04.2024 | The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months | Markets The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
William Edwards
2024-04-04T14:09:13Z
Share icon An curved arrow pointing ri... |
| 17.03.2024 | Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year | Economy Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
George Glover
2024-03-17T08:31:02Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
F... |
| 13.03.2024 | New Employee Elected Directors to the Board of Zealand Pharma A/S | - |
| 08.03.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | - |
| 05.03.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | - |
| 05.03.2024 | Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants | - |
| 22.12.2023 | Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank | - |
| 18.09.2023 | Is Denmark Setting the Global Standard in Peptide-Based Biopharmaceutical Innovation? | Key Takeaways:
Zealand Pharma, based in Denmark, is a leader in peptide-based biopharmaceutical innovation.
Through a variety of partnerships and proprietary developments, Zealand Pharma has made significant strides in developing peptide-ba... |
| 17.08.2023 | Zealand Pharma Announces Financial Results for the First Half of 2023 | Company announcement - No. 28 / 2023
Zealand Pharma Announces Financial Results for the First Half of 2023
Strong progress across R&D pipeline and significant strengthening of the balance sheet
Boehringer Ingelheim to move into Phase 3 ... |
| 30.06.2023 | Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism | /EIN News/ -- Press release – No. 8 / 2023
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a bio... |
| 11.10.2022 | Zealand Pharma major shareholder announcement: Polar Capital | Company announcement – No. 47 / 2022
Zealand Pharma major shareholder announcement: Polar Capital
Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based ... |
| 10.10.2022 | Zealand Pharma major shareholder announcement: Van Herk Investments | /EIN News/ -- Company announcement – No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78)... |
| 10.10.2022 | Zealand Pharma major shareholder announcement: Van Herk Investments | Company announcement – No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen... |
| 13.09.2022 | Zealand Pharma grants warrants to employees in Denmark | Company announcement – No. 40 / 2022
Zealand Pharma grants warrants to employees in Denmark
Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechn... |
| 30.06.2022 | Total number of shares and voting rights in Zealand Pharma at June 30, 2022 | Company announcement – No. 30 / 2022
Total number of shares and voting rights in Zealand Pharma at June 30, 2022
Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhage... |
| 10.06.2022 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 | Company announcement – No. 28 / 2022
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen... |
| 19.05.2022 | Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) | Company announcement – No. 22 / 2022
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) Dasiglucagon met the primary endpoint with statistical significanc... |
| 10.05.2022 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 | Company announcement – No. 17 / 2022
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Copenhagen, DK and Boston, MA, May 10 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-... |
| 07.04.2022 | Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022 | Company announcement – No. 13 / 2022
CORRECTION: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022
Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 7... |
| 07.04.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022 | Company announcement – No. 13 / 2022
Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022
Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78)... |
| 30.03.2022 | Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations | Company announcement – No. 10 / 2022
Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations Dr. Adam Steensberg assumes the position of Chief Executive Off... |
| 11.03.2022 | Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. | Company announcement – No. 9 / 2022
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
Full Year Results for 2021
Copenhagen, ... |
| 10.03.2022 | Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. | Company announcement – No. 7 / 2022
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
Full Year Results for 2021
Copenhagen, ... |
| 25.02.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022 | Company announcement – No. 5 / 2022
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022
Copenhagen, DK and Boston, MA, February 25, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a C... |
| 20.01.2022 | Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 3 / 2022
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending p... |
| 19.01.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 | Company announcement – No. 2 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022
Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 7... |
| 19.01.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 | Company announcement – No. 2 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022
Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 7... |
| 30.12.2021 | Total number of shares and voting rights in Zealand Pharma at December 30, 2021 | Company announcement – No. 78 / 2021
Total number of shares and voting rights in Zealand Pharma at December 30, 2021
Copenhagen, DK and Boston, MA, December 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a C... |
| 24.12.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 77 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, December 24, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a... |
| 24.12.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 77 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, December 24, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a... |
| 16.12.2021 | Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 76 / 2021
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Interim analysis for the trial exp... |
| 16.12.2021 | Zealand Pharma A/S : Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital - Form 6-K | Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
· Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note
· The non-dilutive debt facility will s... |
| 16.12.2021 | Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 76 / 2021
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Interim analysis for the trial exp... |
| 14.12.2021 | Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital | Company announcement – No. 75 / 2021
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note
The ... |
| 14.12.2021 | Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital | Company announcement – No. 75 / 2021
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note
The ... |
| 10.12.2021 | Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | Company announcement – No. 74 / 2021
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. December 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ... |
| 10.12.2021 | Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | Company announcement – No. 74 / 2021
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. December 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ... |
| 30.11.2021 | Total number of shares and voting rights in Zealand Pharma at November 30, 2021 | Company announcement – No. 72 / 2021
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a C... |
| 30.11.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 73 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a ... |
| 30.11.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 73 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a ... |
| 29.11.2021 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 | Company announcement – No. 71 / 2021
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copen... |
| 29.11.2021 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 | Company announcement – No. 71 / 2021
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copen... |
| 23.11.2021 | Zealand Pharma A/S : announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide - Form 6-K | Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
Company announcement - No. 70 / 2021
• Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosi... |
| 20.11.2021 | Zealand Pharma A/S : Company announcement – No. 69/ 2021 Company announcement – No. 69 / 2021 - Form 6-K | Company announcement - No. 69/ 2021
Company announcement - No. 69 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. November 19, 2021 - Zealand Pharma A/S... |
| 19.11.2021 | Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | Company announcement – No. 69/ 2021
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. November 19, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a... |
| 12.11.2021 | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinic... | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical Studies
Copenhagen, DK and Boston, MA... |
| 12.11.2021 | Zealand Pharma to Participate in Jefferies London Healthcare Conference | Company announcement – No. 68 / 2021
Zealand Pharma to Participate in Jefferies London Healthcare Conference
Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology compa... |
| 11.11.2021 | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinic... | Company announcement – No. 67/ 2021
Interim report for 9M 2021
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Synd... |
| 11.11.2021 | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinic... | Company announcement – No. 67/ 2021
Interim report for 9M 2021
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Synd... |
| 04.11.2021 | Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity | Company announcement – No. 65/ 2021
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity
Preclinical data have shown potent anti-obesity effects of ZP8396 both as a monotherapy... |
| 04.11.2021 | Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021 | Company announcement – No. 64 / 2021
Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021
Copenhagen, DK and Boston, MA, U.S. November 4, 2021 – Zealand Pharma A/S (Nasdaq: ZEA... |
| 01.11.2021 | Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting | Company announcement – No. 63 / 2021
Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting Preclinical data sh... |
| 01.11.2021 | Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting | Company announcement – No. 63 / 2021
Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting Preclinical data sh... |
| 19.08.2021 | Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 52 / 2021
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
The EASE-SBS 4 Phase 3b trial will evaluate long-term effect on inte... |
| 12.08.2021 | Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas | Company annoucement - No. 50 / 2021
Interim report for H1 2021
Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas
Copenhagen, DK and Boston, MA, U.S. August 12, 2021 ... |
| 24.06.2021 | Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection | Company announcement – No. 41/ 2021
Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection ZEGALOGUE now available in both an auto-injector and prefilled syringe for the treatment of severe hypoglycemia... |
| 16.06.2021 | ZEALAND PHARMA A/S
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions | Company announcement – No. 39/2021
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
Company to present six abstracts on ZEGALOGUE® (dasiglucagon) injection... |
| 02.06.2021 | ZEALAND PHARMA A/S
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH | Company announcement – No. 35/ 2021
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent ne... |
| 01.06.2021 | Minutes from the Extraordinary General Meeting in Curasight A/S | Minutes from the Extraordinary General Meeting in Curasight A/S Tue, Jun 01, 2021 12:01 CET
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the CO... |
| 27.05.2021 | ZEALAND PHARMA A/S
Zealand Pharma A/S : launches long-term incentive program for Zealand's US based Corporate Management for 2021 | Company announcement – No. 33 / 2021
Zealand Pharma launches long-term incentive program for Zealand’s US based Corporate Management for 2021
Copenhagen, DK and Boston, MA, U.S., May 27, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) ... |
| 18.05.2021 | Notice of Extraordinary General Meeting | Notice of Extraordinary General Meeting Tue, May 18, 2021 13:00 CET
Copenhagen, Denmark, 18 May 2021 – Notice is hereby given of an extraordinary general meeting of Curasight A/S to be held on:
Tuesday, 1 June 2021 at 11:00 am CET
Due to th... |
| 12.05.2021 | ZEALAND PHARMA A/S
Zealand Pharma A/S : launches long-term incentive program for Zealand's Executive Management and employees for 2021 | Company announcement – No. 28/ 2021
Zealand Pharma launches long-term incentive program for Zealand’s Executive Management and employees for 2021
Copenhagen, DK and Boston, MA, U.S. May 5, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 2... |
| 29.04.2021 | ZEALAND PHARMA A/S
Zealand Pharma A/S : launches long-term incentive program for Zealand's Board of Directors and grants for 2021 | Company announcement – No. 23 / 2021
Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors and grants for 2021
Copenhagen, DK and Boston, MA, U.S., April 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 2... |
| 10.08.2017 | Zealand bags a $77M IPO haul as investors embrace another biotech offering | Copenhagen-based Zealand Pharma is the latest biotech to march out onto Nasdaq this year. The peptide drug developer — closely allied with Sanofi — raised $77 million after selling an upsized package of 4.4 million shares a... |
| 09.08.2017 | Term Sheet — Wednesday, Aug. 9 | ET CETERA
Good morning! I’m attending to some magazine duties today, so here’s some news from my Fortune colleagues:
Paid Content What you need to know about growing cyberattacks From ExtraHop
The event itself was elaborate. After arriving ... |
| 03.08.2017 | Term Sheet — Thursday, Aug. 3 | MARKDOWNS AGAIN
After we wrote about mutual fund markdowns to Uber’s share price, a few readers wrote in asking how mutual funds determine their markdowns.
Paid Content What you need to know about growing cyberattacks From ExtraHop
• This i... |
| 07.07.2017 | Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII | Copenhagen-based Zealand Pharma is following a clearly blazed trail from Europe to Nasdaq in search of an IPO that can help fund a pair of late-stage drugs.
Following the upbeat results for AC Immune (Switzerland) $ACIU and Ar... |
